Role of apoptosis-inducing factor, proline dehydrogenase, and NADPH oxidase in apoptosis and oxidative stress

Sathish Kumar Natarajan
Donald F Becker

Department of Biochemistry and Redox Biology Center, University of Nebraska-Lincoln, Lincoln, NE

Abstract: Flavoproteins catalyze a variety of reactions utilizing flavin mononucleotide or flavin adenine dinucleotide as cofactors. The oxidoreductase properties of flavoenzymes implicate them in redox homeostasis, oxidative stress, and various cellular processes, including programmed cell death. Here we explore three critical flavoproteins involved in apoptosis and redox signaling, ie, apoptosis-inducing factor (AIF), proline dehydrogenase, and NADPH oxidase. These proteins have diverse biochemical functions and influence apoptotic signaling by unique mechanisms. The role of AIF in apoptotic signaling is two-fold, with AIF changing intracellular location from the inner mitochondrial membrane space to the nucleus upon exposure of cells to apoptotic stimuli. In the mitochondria, AIF enhances mitochondrial bioenergetics and complex I activity/assembly to help maintain proper cellular redox homeostasis. After translocating to the nucleus, AIF forms a chromatin degrading complex with other proteins, such as cyclophilin A. AIF translocation from the mitochondria to the nucleus is triggered by oxidative stress, implicating AIF as a mitochondrial redox sensor. Proline dehydrogenase is a membrane-associated flavoenzyme in the mitochondrion that catalyzes the rate-limiting step of proline oxidation. Upregulation of proline dehydrogenase by the tumor suppressor, p53, leads to enhanced mitochondrial reactive oxygen species that induce the intrinsic apoptotic pathway. NADPH oxidases are a group of enzymes that generate reactive oxygen species for oxidative stress and signaling purposes. Upon activation, NADPH oxidase 2 generates a burst of superoxide in neutrophils that leads to killing of microbes during phagocytosis. NADPH oxidases also participate in redox signaling that involves hydrogen peroxide-mediated activation of different pathways regulating cell proliferation and cell death. Potential therapeutic strategies for each enzyme are also highlighted.

Keywords: apoptosis, flavoproteins, apoptosis-inducing factor, NADPH oxidase, proline dehydrogenase

Introduction

Apoptosis is a controlled, genetically regulated form of cell death. The term apoptosis (Greek, meaning “falling off”) was coined by Kerr et al in the early 1970s to describe the mechanism of programmed cell death in healthy human tissues.1 Programmed cell death is an evolutionarily conserved form of cell suicide and is crucial in plants and animals.2–5 This review will focus on the role of flavoproteins in programmed cell death and the interrelated extrinsic and intrinsic pathways of apoptosis. The mechanisms by which three different flavoproteins, ie, apoptosis-inducing factor (AIF), proline dehydrogenase, and NADPH oxidase, contribute to apoptosis and oxidative stress are described, along with therapeutic strategies for disease intervention.
Extrinsic and intrinsic pathway of apoptosis

Several comprehensive reviews are available for extrinsic and intrinsic apoptosis. Here we will only summarize some of the main features of extrinsic and intrinsic apoptosis. The extrinsic pathway of apoptosis is mediated at the cell surface by various death receptors such as Fas, tumor necrosis factor (TNF) receptor 1, death receptor (DR)3, TNF-related apoptosis-inducing ligand (TRAIL) receptor 1, and TRAIL R2, DR6, p75 nerve growth factor receptor, and ectodermal dysplasia receptor. Death receptors are activated by specific ligands, such as the Fas ligand, TNFα, and TRAIL. Ligand binding to death receptors transmits signals that result in recruitment of intracellular death domain-binding partners, such as Fas-associated death domain and TNF receptor-associated death domain. The Fas receptor-Fas-associated death domain complex leads to recruitment of specific adaptor proteins to form a larger complex, termed the death-inducing signaling complex, which subsequently activates procaspases 8 and 10. Activated caspases 8 and 10 then activate downstream caspases 3, 6, and 7. These activated caspases cleave nuclear DNA repair enzymes and other cellular proteins, such as poly(ADP-ribose) polymer (PARP), cytosolic phospholipase A2, actin, and lamin, leading to the formation of apoptotic bodies, chromatin condensation, and DNA fragmentation.

The intrinsic or mitochondrial apoptotic pathway is primarily initiated in response to cellular oxidative stress or DNA damage. Ultraviolet radiation or DNA-damaging drugs induce the intrinsic pathway via p53-mediated transcriptional upregulation of proapoptotic factors of B cell lymphoma 2 (BCL-2) family members such as BAX, APAF-1, PUMA, and NOXA genes. These proapoptotic factors inhibit the action of antiapoptotic BCL-2 mediators like BCL-xL, BCL-w, and myeloid cell factor-1. Upregulation of the p53 modulator of apoptosis and other factors, such as dynamin-related protein-1 (a GTPase) and BCL-w, and myeloid cell factor-1. These activated caspases cleave nuclear DNA repair enzymes and other cellular proteins, such as poly(ADP-ribose) polymer (PARP), cytosolic phospholipase A2, actin, and lamin, leading to the formation of apoptotic bodies, chromatin condensation, and DNA fragmentation.

Apoptosis-inducing factor

The role of AIF in mitochondrial processes and apoptosis has been an interesting area of research since the discovery of AIF in 1999. The initial identification of AIF as a flavoprotein suggested that it was a novel mitochondrial redox sensor. Subsequent studies have established that AIF is a proapoptotic bifunctional protein that exhibits distinct functions according to its compartmentalization in either the mitochondria or the cell nucleus. However, the physiological function of AIF in the mitochondria and the mechanisms by which it induces chromatinolysis and cell death are not yet fully known.

Newly synthesized AIF is targeted to the intermembrane space of the mitochondria where flavin adenine dinucleotide (FAD) is incorporated into the folded protein. A transmembrane peptide at the N-terminus of AIF anchors it to the inner mitochondrial membrane. The mature form of AIF appears to have a stabilizing influence on complex I activity of the respiratory chain. In response to apoptotic stimuli such as oxidative stress, AIF is proteolytically cleaved into a soluble form that translocates to the cell nucleus. Once in the nucleus, AIF facilitates chromatin condensation and DNA fragmentation, leading to apoptosis. Thus, similar to cytochrome c, AIF is a mitochondrial protein that is released into the cytosol and translocated to the nucleus, resulting in apoptosis. However, the mechanisms by which AIF participates in apoptosis are distinct from the intrinsic pathway involving cytochrome c and are caspase-independent. In the following sections, we review the structure and biochemical functions of AIF, translocation mechanisms, and the role of AIF in apoptosis and disease.
AIF structure

Human AIF is encoded as a 67 kDa polypeptide with 613 residues. The precursor protein contains a mitochondrial localization sequence (residues 1–55), a transmembrane region (residues 66–84), an FAD binding domain (residues 128–262 and 401–480), an NADH binding domain (residues 263–400), a nuclear localization sequence (residues 446–452), and a C-terminal domain (residues 481–613), which has a proline-rich motif (residues 543–554) and a proline/glutamate/serine/threonine sequence (residues 528–559). AIF does not have a canonical DNA binding domain; instead, DNA binding is mediated by positively charged residues from the FAD and C-terminal domains that form favorable electrostatic interactions between AIF and DNA. The mature form of AIF (residues 55–613, 57 kDa) is generated by removal of the mitochondrial localization signal peptide and is anchored to the inner mitochondrial membrane via the transmembrane binding peptide.

The structure of NADH-treated AIF with the FAD cofactor in the reduced form was reported, enabling comparison of the oxidized and reduced forms of AIF. Oxidized AIF is a monomer, whereas NADH reduction of the FAD cofactor generates an AIF dimer. The crystal structure indicates that changes on the surface of AIF occur upon reduction, promoting dimeric interactions. Also, the nuclear localization sequence is less solvent-accessible in the dimeric structure, suggesting translocation into the nucleus would be impeded for the AIF dimer relative to the monomeric form.

Functions of AIF

AIF exhibits distinct functions depending on its subcellular localization in the cell. In the mitochondria, studies have focused on characterizing the enzymatic activity of AIF with NADPH and its contribution to mitochondrial function. The FAD cofactor in AIF can be reduced by both NADH and NADPH, but NADH is the preferred reducing substrate (100-fold preference). However, the rate of reduction of AIF by NADH is relatively slow in comparison with other flavoenzymes, such as NADPH:quinone oxidoreductase. Upon reduction by NADH, a charge transfer complex is formed between FADH\(^+\) and bound NAD\(^-\). Interestingly, the FADH\(^+\)-NAD\(^-\) charge transfer complex is very stable in air, with reduced AIF exhibiting a high affinity for NAD\(^-\) (\(K_d\) of 5–80 nM).

AIF has been reported to generate superoxide, but the sluggish activity of reduced AIF with oxygen argues against AIF having meaningful NADH oxidase activity in vivo. Recently, Misevićiene et al tested the reactivity of mouse AIF with different quinones. AIF exhibited NADH:quinone oxidoreductase activity, but the rate was much lower (10\(^{4}\)-fold lower) than that of other quinone reductases, such as NADPH:quinone oxidoreductase. Thus, it was concluded that AIF does not contribute significantly to reduction of quinone drugs in vivo. Whether the quinone reductase activity of AIF is physiologically important is not clear. It was suggested that reactivity of AIF with quinones may interfere with NADH reduction of AIF and the overall redox homeostasis of mitochondrial AIF. Clearly, further studies are needed to identify other potential oxidizing substrates of AIF.

Despite not having a clear enzymatic role, it is well established that AIF has a significant influence on mitochondrial function. Studies have shown that AIF deficiency or low expression of AIF generally decreases oxidative phosphorylation, even though AIF is not part of complex I in the electron transport chain. Changes in AIF expression are strongly correlated with mitochondrial complex I activity, with loss of mitochondrial AIF generally leading to increased oxidative stress. Inactivation of AIF in the early mouse embryo impaired respiratory complex I activity and led to increased cell death. Thus, reduction of AIF function leads to lower mitochondrial respiration and altered energy metabolism.

Other results supporting a role for AIF in respiratory activity are from studies of AIF-deficient mice harboring a proviral insertion in the AIF gene, known as the Harlequin mutation. Knockout of AIF in mice is embryonically lethal, so Harlequin (Hq) mice are a widely used AIF-deficient animal model used to study the deficiency of AIF. In Hq mice, AIF expression is decreased by 80%–90% relative to wild-type mice, making these mice a useful model for evaluating the physiological role of AIF in complex I function and oxidative phosphorylation. The Hq mice are characterized by a 50% drop in complex I activity, and show evidence of elevated oxidative stress in the heart, brain, and cerebellum, with increased lipid peroxidation and mitochondrial DNA damage. In addition, T cells isolated from Hq mice are more sensitive to Fas ligand-induced cell death than are wild-type controls. Hq mice are also resistant to cell death induced by the PARP activator, which suggests a role for AIF in PARP activation. The observation of increased oxidative stress in Hq mice led to the proposal that AIF functions as an antioxidant enzyme. However, in vitro knockdown studies of AIF did not provide solid evidence for AIF having an antioxidant role. AIF-deficient cells were shown to have a dramatic loss of cell tumorigenicity in mice due to the loss of complex I activity. More studies are needed to understand the molecular details of how AIF...
influences redox homeostasis and protects complex I activity and mitochondrial bioenergetics.36,45

In the nucleus, the function of AIF is to promote chromatin condensation and DNA fragmentation. Thus, attention has focused on understanding the DNA binding properties of AIF and the mechanisms by which it initiates DNA fragmentation and apoptotic events. As mentioned above, AIF does not have a canonical DNA binding domain, but x-ray crystal structures of AIF have revealed positively charged surface areas that are complementary to the negatively charged phosphate backbone of the DNA.29,46 AIF has been shown to bind double-stranded and single-stranded DNA and RNA.47 AIF-DNA binding leads to condensation of the DNA, possibly through cooperative interactions of AIF proteins on the DNA.47 Thus, AIF-DNA interactions alone are sufficient to generate higher-ordered DNA structures, which presumably would facilitate chromatin condensation, a fundamental feature of apoptosis.47 The mechanisms by which AIF contribute to DNA fragmentation in the nucleus are less certain. It appears that AIF lacks nuclease activity, so AIF most likely helps to recruit other proteins to the DNA for chromatin degradation. One such protein is cyclophilin A, which normally catalyzes the cis-trans isomerization of peptidyl-prolyl bonds in target proteins, but has also been reported to have calcium-dependent nuclelease activity.48 Although AIF shows no independent DNA nicking activity, the combination of AIF and cyclophilin A caused degradation of plasmid DNA in vitro, suggesting that AIF and cyclophilin A may work synergistically in the nucleus to degrade chromatin.49 A cyclophilin A interaction domain of about 30 amino acids (367–399) in AIF was identified, supporting the formation of an AIF-cyclophilin A complex.49 More recently, it was found that AIF interacts with histone H2AX, a member of the histone H2A family and part of the histone nucleosome core.50 Interactions between AIF and H2AX were suggested to involve the proline-rich motif of AIF.50 It was proposed that AIF, cyclophilin A, and H2AX form a complex in the nucleus that promotes chromatinolysis and programmed cell death. H2AX most likely provides AIF/cyclophilin A with access to the DNA to facilitate degradation of chromatin (see Figure 1).

**AIF translocation and redox regulation**

The function of AIF is determined by its localization in the cell. Thus, understanding the regulation of AIF localization is critical to understanding the mechanisms by which AIF induces apoptosis. Figure 1 summarizes the overall mechanism of AIF translocation to the nucleus and activation of apoptosis. The mitochondrial location of AIF and its relationship with complex I activity indicates a possible redox mechanism for AIF regulation. Evidence for redox regulation of AIF has been reported from analysis of the AIF oligomeric structure. In the presence of NADH, AIF is primarily a dimer whereas in the absence of NADH, AIF is mainly a monomer.29 Thus, AIF exists in dimer-monomer equilibrium, with NADH reduction of the bound FAD favoring the dimeric form and oxidation driving formation of the AIF monomer.29 AIF localization in the inner mitochondrial membrane is ideal for responding to intracellular redox changes, such as the NADH/NAD+ ratio. Decreased NADH levels associated with oxidative stress and apoptotic insults would be predicted to shift AIF toward the monomeric form.30 The significance of the redox regulation of AIF dimer-monomer equilibrium is that the AIF monomer appears to have increased susceptibility to proteolysis at the N-terminal membrane binding domain. Apoptotic AIF is generated by proteolytic processing of mature AIF upon apoptotic insult, oxidative stress, or mitochondrial membrane rupture. In particular, the Ca2+-dependent cysteine protease, µ-calpain (also known as calpain-I), is thought to have a major role in protease-dependent release of AIF from the mitochondrial inner membrane.3,8,45,51 Treatment of isolated mitochondria with a calpain inhibitor abolished AIF release.26 Thus, oxidative conditions which favor the monomeric form of AIF also lead to increased proteolytic susceptibility and processing.

Newly cleaved AIF breaks out of the mitochondria by traversing BAX/BAK pores in the outer mitochondrial membrane.27 AIF can also escape from the inner mitochondrial membrane space via the mitochondrial permeability transition pores. This was shown by inhibition of AIF release by cyclosporin A, a permeability transition pore inhibitor.32 AIF release is also diminished by increased expression of BCL-2, an antiapoptotic protein which prevents formation of the mitochondrial membrane transition pore. Although liberation of AIF from the mitochondria is caspase-independent, it has been suggested that caspases increase mitochondrial permeabilization and thereby facilitate calpain-dependent release of AIF from the mitochondria.50,52 A consequence of AIF proteolysis and release from the inner membrane space is decreased complex I activity and oxidative phosphorylation. These effects eventually lead to increased generation of reactive oxygen species, mitochondrial swelling, and rupture of the outer membrane, resulting in accelerated release of AIF from the mitochondria.30
Upon leaving the mitochondria, AIF translocates to the cell nucleus where it assumes its apoptotic function. AIF has also been proposed to interact with a number of functionally diverse proteins in the cytosol that either inhibit or enhance its translocation to the cell nucleus. For example, heat shock protein (HSP)70 has been shown to intercept AIF en route to the nucleus, forming an AIF-HSP70 complex and thereby retaining AIF in the cytosol and inhibiting apoptosis. Interactions between AIF and cyclophilin A seem to enhance translocation of AIF into the nucleus because AIF fails to induce apoptosis in cyclophilin A knockout cells. AIF has also been suggested to interact with phospholipid scramblase (an ATP-dependent phospholipid translocating enzyme), eukaryotic translation initiation factor 3, thioredoxin 2, T-cell ubiquitin ligand, and scythe. All of these proteins have been proposed to promote AIF translocation into the nucleus. Scythe (HLA-B-associated transcript 3) is a regulator of apoptosis in mammalian development. Inactivation of scythe in mice leads to embryonic or perinatal lethality due to development defects consistent with it having a role in facilitating the apoptotic function of AIF. Scythe-deficient cells are less sensitive to endoplasmic reticulum stress-induced apoptosis. Desmots et al demonstrated that scythe interacts with AIF in the cytosol in response to stress on the endoplasmic reticulum. It was proposed that AIF-scythe interaction functions as a regulatory complex to enhance apoptogenic activity of AIF.

Another mechanism of AIF translocation relates to parthanatos cell death involving interactions with PARP.
Activation of PARP-1, a nuclear DNA repair enzyme, leads to increased levels of poly(ADP-ribose) (PAR), which subsequently increase AIF translocation to the nucleus.\textsuperscript{27,56} PAR have been shown to bind to AIF in the mitochondria, forming an AIF-PAR complex that escapes from the mitochondria and translocates to the nucleus, resulting in chromatin condensation and DNA cleavage during parthanatos.\textsuperscript{55} Recently, Wang et al identified a PAR-binding site in AIF which is distinct from its DNA binding site.\textsuperscript{37} The functional importance of the PAR binding site was demonstrated by characterization of the triple PAR binding mutant (Pbm)-AIF (R588A, K592A). Pbm-AIF defective in PAR binding was not translocated to the nucleus by activation of PARP-1 in response to cellular DNA damage.\textsuperscript{57} The small pool of AIF present in the outer mitochondrial membrane of the rat brain has also been proposed to translocate rapidly to the nucleus in response to PAR-induced parthanatos.\textsuperscript{58}

Implications in disease

A deletion mutation in the \textit{AIF} gene has been associated with the severe X-linked mitochondrial encephalomyopathy disorder characterized by axonal sensory and motor peripheral neuropathy, and severe muscular atrophy. A deletion of base pairs 601–603 in exon 5 of the \textit{AIF} gene results in the loss of the Arg201 codon.\textsuperscript{31} The AIF Arg201\textsubscript{Δ} mutant has been found in two patients.\textsuperscript{31} In the structure of human AIF, Arg201 (Arg 200 in the mouse) was shown to be part of the 191–203 β-hairpin which helps to form the FAD binding pocket and gives conformational stability to the flavoprotein. Arg201 was also observed to form a salt bridge with Glu531. The importance of Arg201 in FAD binding was further demonstrated by characterization of the AIF Arg201\textsubscript{Δ} mutant protein, which was found to contain less FAD relative to wild-type AIF.\textsuperscript{31} Thus, the deletion of the Arg201 codon has a clear functional consequence that leads to a less stable AIF protein.

Fibroblasts isolated from patients with AIF Arg201\textsubscript{Δ} showed partially reduced mitochondrial complex I, III, and IV activity and decreased oxidative phosphorylation.\textsuperscript{31} These fibroblasts upon exposure to staurosporine, a protein kinase C inhibitor that induces cell death through the mitochondria-mediated pathway, showed significantly higher levels of morphologically altered nuclei than control fibroblasts.\textsuperscript{31} Electron microscopy of fibroblasts from AIF Arg201\textsubscript{Δ} patients showed typical features of parthanatos, with high chromatinolysis but without any apoptotic bodies.\textsuperscript{31} These results suggested that the chromatinolysis activity of AIF is higher in the AIF Arg201\textsubscript{Δ} mutant relative to wild-type AIF. Treatment with riboflavin, an FAD precursor, partially improved mitochondrial complex I activities and staurosporine-induced cell death in AIF mutant fibroblasts.\textsuperscript{31} In addition, prolonged riboflavin supplementation was reported to ameliorate the clinical status of an AIF Arg201\textsubscript{Δ} patient.\textsuperscript{31} Further studies are needed to test and evaluate the prevalence of this mutation in other populations and the efficacy of riboflavin supplementation.

Another human disease related to AIF is familial autosomal dominant optic atrophy caused by mutations in the \textit{OPA1} gene which encodes optic atrophy 1 (OPA1), a dynamin GTPase. Dominant optic atrophy is characterized by blindness due to the loss of retinal ganglion cells, leading to optic neuropathy.\textsuperscript{59} Zanna et al showed OPA1 improved activity of mitochondrial complex enzymes by direct interactions with mitochondrial complex proteins, including AIF.\textsuperscript{59} Future studies are required to understand how AIF-OPA1 interactions influence mitochondrial complex I activity.

Recent evidence suggests an important apoptotic role for AIF in intestinal epithelial cells exposed to pathogenic bacteria. Infecting adenocarcinoma cells with \textit{Helicobacter pylori} or human epithelial cells with \textit{Actinobacter baumanii} and \textit{Pseudomonas aeruginosa} induces apoptosis and has been shown to involve AIF.\textsuperscript{60–63} AIF has also been implicated in intestinal epithelial apoptotic cell death upon exposure of cells to \textit{Citrobacter rodentium} and enteropathogenic \textit{Escherichia coli}.\textsuperscript{63,64} Knockdown of AIF in HeLa cells by siRNA blocked apoptosis induced by enteropathogenic \textit{E. coli}, providing further evidence for an important apoptotic role of AIF in bacterial infections in the gut.\textsuperscript{63}

Therapeutic outlook

Studies investigating the therapeutic potential of AIF have pursued strategies for either blocking or increasing AIF apoptotic activity. One approach for interfering with AIF apoptosis involves HSP70. As noted above, HSP70 is a cytosolic binding partner of AIF and acts to sequester AIF in the cytosol, blocking the apoptotic activity of AIF. Apoptosis and gastric lesions in the small intestine induced by the nonsteroidal anti-inflammatory drug, indomethacin, were significantly decreased in transgenic mice overexpressing HSP70.\textsuperscript{65} These transgenic mice were also protected against neonatal hypoxic-ischemic brain injury due to increased sequestering of AIF in the cytosol and therefore lower AIF-dependent apoptosis.\textsuperscript{66} Mice lacking HSP70 show increased apoptosis in the heart after ischemia-reperfusion, providing additional evidence for the regulation of AIF apoptosis by HSP70.\textsuperscript{67}
An HSP70 gene polymorphism has been shown to be associated with schizophrenia, but whether the underlying mechanisms involved alter AIF apoptotic activity remains unknown. Studies of AIF binding to the HSP70 mutant would provide important insights into this question.

Strategies that prevent AIF release from the mitochondria have also been pursued. Calpain inhibitors, such as MDL28170, PD150606, AK275, and AKT295, have been shown to block AIF release in rat models of ischemia, Parkinson's disease, and retinitis pigmentosa, suggesting a new therapeutic approach. INO1-1001, a PARP-1 inhibitor, improves the function of the perfused heart in diabetic rat models. Inhibition of PARP-1 is predicted to decrease AIF release from the mitochondria and apoptosis. Thus, drugs that target PARP-1 block AIF apoptosis which would be a potential therapeutic benefit in the treatment of myocardial ischemia.

Approaches to activate AIF apoptotic function have been of primary interest in cancer research. Overexpression of AIF in gastric cancer, hepatocellular carcinoma cells, and osteosarcoma cells resulted in increased drug-induced apoptosis. Thus, various therapeutic methods to increase AIF apoptotic activity have been explored. Drugs that target AIF release and apoptosis induction in cancer have recently been reviewed. Here, we will discuss just a few of the approaches.

One study sought to diminish the sequestering of AIF in the cytosol by disrupting HSP70-AIF interactions. In a colon cancer model, rats injected with the synthetic AIF peptide (150–228 residues) exhibited an improved response with cisplatin-induced apoptosis.

A kinetic study of purified human proline dehydrogenase has not yet been performed, but significant insights have been gained from the related proline utilization A (PutA) enzyme in Gram-negative bacteria and proline dehydrogenase from Thermus thermophilus (TtPRODH). PutA is a bifunctional enzyme which combines proline dehydrogenase and P5C dehydrogenase domains in the same polypeptide. The proline dehydrogenase domain in PutA from E. coli and TtPRODH share high sequence conservation in the active site with human proline dehydrogenase, thus providing important insights into the mechanism and structure of human proline dehydrogenase. The proline dehydrogenase domain of PutA (PutA/PRODH) and TtPRODH is a (βα)6 barrel core structure that noncovalently binds the FAD cofactor. The (βα)6 barrel core is predicted to be similar to the catalytic core of human proline dehydrogenase. Residues that are critical for proline binding in E. coli PutA, such as Arg555 and Arg556, are conserved in human proline dehydrogenase (Arg479 and Arg480). The proline dehydrogenase reaction can be separated into reductive and oxidative half-reactions. In the reductive half-reaction, proline dehydrogenase catalyzes the two-electron oxidation of proline, forming FADH2 and P5C. The reductive half-reaction has been proposed to occur by a hydride transfer mechanism from proline to the FAD bound in E. coli PutA/proline dehydrogenase. In the oxidative half-reaction, PutA/proline dehydrogenase catalyzes the electron transfer from reduced FAD to membrane-bound ubiquinone. The kinetic mechanism of the
proline:ubiquinone oxidoreductase reaction was recently shown to occur for PutA/proline dehydrogenase via a ping-pong mechanism with proline and ubiquinone binding at two distinct sites. Human proline dehydrogenase may use a similar mechanism for transferring reducing equivalents from FADH$_2$ to ubiquinone in the mitochondrial electron transport chain.

**Apoptosis and signaling**

PRODH1 is a p53-inducible gene (PIG6) that has a crucial role in apoptosis. The mechanisms involving proline dehydrogenase and induction of apoptosis are illustrated in Figure 2. Overexpression or upregulation of proline dehydrogenase leads to increased proline oxidation in the mitochondria and superoxide production. In colon cancer cells expressing wild-type p53, proline dehydrogenase expression was induced by adriamycin, whereas in cells that lacked a functional p53, proline dehydrogenase expression was unresponsive to adriamycin. Thus, cytotoxic drugs such as adriamycin that cause DNA damage and apoptosis induce proline dehydrogenase expression via p53.

The mechanism by which proline dehydrogenase contributes to apoptosis has been carefully studied by Phang et al. Upregulation of proline dehydrogenase expression by p53 results in increased reactive oxygen species levels which initiate the intrinsic and extrinsic apoptotic cell death pathways. Intrinsic apoptosis is generally characterized by elevated levels of mitochondrial reactive oxygen species resulting in mitochondrial membrane damage, cytochrome c and AIF release, and activation of caspase 9. Consistent with intrinsic apoptosis, increased proline dehydrogenase expression causes cytochrome c release and caspase 9 activation. Addition of proline to proline dehydrogenase-overexpressing cell lines further augments reactive oxygen species-mediated cytochrome c release and caspase 9 activation. Proline dehydrogenase-induced apoptosis is inhibited in cells overexpressing manganese superoxide dismutase, consistent with an important role for reactive oxygen species in proline dehydrogenase-mediated apoptosis. In addition, P5C generated by proline dehydrogenase has been shown to promote apoptosis in bladder carcinoma cell lines and inhibit cell proliferation.

**Figure 2** Proline dehydrogenase and classical apoptotic pathway. DNA damage induces both the extrinsic and intrinsic pathway of apoptosis by increasing the expression of death receptors and p53, respectively. Proline dehydrogenase in the mitochondria is upregulated by p53. Oxidation of proline by proline dehydrogenase leads to production of pyrroline-5-carboxylate (P5C) and FADH$_2$. Electrons from FADH$_2$ are then transferred to the electron transport chain to produce ATP for survival or superoxide (O$_2^-$) and oxidative stress in the mitochondria. Oxidative stress generated by proline dehydrogenase induces the release of cytochrome c from the mitochondria, resulting in the formation of an apoptosome involving activated caspase 9, which then activates downstream caspases 3, 6, and 7 to induce apoptosis. It is not known whether proline dehydrogenase also induces mitochondrial release of AIF.

**Abbreviations:** PRODH, proline dehydrogenase; AIF, apoptosis inducing factor; cyt c, cytochrome c; FAD, flavin adenine dinucleotide; FADD, Fas-associated death domain; ETC, electron transport chain; BID, BCL-2 interacting domain; tBID, truncated BCL-2 interacting domain.
Thus, the contribution of proline dehydrogenase to apoptosis may be two-fold, involving reactive oxygen species and the intrinsic apoptotic pathway, as well as P5C. Whether proline dehydrogenase overexpression causes release of AIF has yet to be determined.

In addition to the mitochondrial apoptotic pathway, evidence has shown for proline dehydrogenase inducing the extrinsic cell death pathway. Liu et al showed proline dehydrogenase upregulates TRAIL and DR5 at the mRNA and protein levels. Also, inhibition of caspase 8 resulted in decreased apoptosis by proline dehydrogenase overexpression. The mechanism of TRAIL upregulation by proline dehydrogenase was shown to be mediated by nuclear factor activated T cells (NFAT). Increased cellular calcium levels are sensed by calmodulin, leading to activation of calcineurin, a Ser/Thr phosphatase known to activate NFAT by dephosphorylation. Activated NFAT then translocates from the cytosol to the nucleus to induce TRAIL expression and apoptosis. Increased reactive oxygen species are well known to affect intracellular calcium homeostasis. Proline dehydrogenase-generated reactive oxygen species were also suggested to mediate the Ca^{2+}/calcineurin-NFAT cascade to activate apoptotic pathways. Peroxisome proliferator-activated receptor γ (PPARγ) ligand has been shown to induce the extrinsic apoptotic pathway in a variety of cancer cells. The mechanism by which the PPARγ ligand, troglitazone, induces apoptosis in colon cancer cell lines involves the upregulation of proline dehydrogenase and increased generation of reactive oxygen species. Triglitazone-induced proline dehydrogenase expression was absent in HCT cells lacking functional p53 and PPARγ, further indicating a role for PPARγ and p53 in the regulation of proline dehydrogenase expression.

Proline dehydrogenase and stress

Proline oxidation plays an important role in cellular redox control that impacts cell survival and cancer cell growth. Earlier work by Phang et al showed that the enzyme actions of proline dehydrogenase and the cytosolic NADPH-dependent P5C reductase (P5CR) form a proline-P5C cycle that effectively shuttles reducing equivalents from the cytosol into the mitochondria. The proline-P5C cycle helps drive the pentose phosphate pathway by replenishing NADPH levels during nutrient stress. Although the proline-P5C cycle seems to have a critical role in cellular redox homeostasis, it is not known yet whether mitochondria have a specific transporter for P5C in mammals.

Proline has also been shown to serve as a microenvironmental stress substrate via proline dehydrogenase to generate ATP for cell survival under poor nutrient conditions (ie, low glucose). Proline dehydrogenase is also induced by AMP-activated protein kinase (AMPK), a central metabolic sensor kinase and an upstream inhibitor of the mammalian target of rapamycin complex 1 activity. During nutrient stress conditions, decreased cellular ATP levels and increased AMP levels act as an allosteric activator of AMPK by binding to one of the subunits of AMPK. Recently, it was shown that glucose deprivation results in increased activity of matrix metalloproteinases 2 and 9, leading to increased intracellular proline levels, higher proline dehydrogenase expression, and increased flux of the pentose phosphate pathway. This study also suggested that the proline oxidation pathway generates glutamate and α-ketoglutarate, which can have an anaplerotic role in the tricarboxylic acid cycle.

We have previously shown that proline supplementation protects mammalian cells against various oxidative stress agents and carcinogen-induced apoptosis. In addition, overexpression of proline dehydrogenase decreases intracellular proline levels and cell survival upon exposure to oxidative stress induced by hydrogen peroxide. The mechanism by which proline protects against oxidative stress is unclear, but our unpublished data indicate that proline dehydrogenase is essential, consistent with the proline-P5C cycle having a significant impact on the intracellular redox state in mammalian cells. Thus, proline dehydrogenase expression levels appear to be pivotal in determining whether proline oxidation has a cell survival role or initiates apoptotic programmed cell death.

Therapeutic outlook

Targeting proline metabolism for potential therapeutic applications seems promising in cancers, schizophrenia, and certain gastrointestinal infections. Proline dehydrogenase expression is downregulated in many cancer tissues such as renal, colon, rectum, stomach, liver, and pancreas. Thus, proline dehydrogenase has been suggested to be a novel mitochondrial tumor suppressor and a potential target for cancer therapy. Recently, ectopic overexpression of miR-23b* in renal cancer cell lines was shown to decrease proline dehydrogenase expression. In miR23b* knockout cells, proline dehydrogenase expression was elevated relative to control cells. It was also confirmed that miR23b* binds to the 3′-untranslated region of proline dehydrogenase mRNA. Thus, it was suggested that inhibiting miR23b* could be a potential strategy for upregulating proline dehydrogenase in renal cancer cells. Additional studies addressing the
upregulation of proline dehydrogenase as a potential cancer therapy are needed.

Inborn errors of proline dehydrogenase are manifested in type I hyperprolinemia and neurological disorders such as schizophrenia and increased incidence of seizures. The PRODH1 gene on chromosome 22q11 is located near the centromeric end of the region which is deleted in Velocardiofacial syndrome/DiGeorge syndrome. Jacquet et al identified a complete deletion of the PRODH1 gene locus in a subset of schizophrenic patients with hyperprolinemia. Another study showed microdeletion of PRODH1 is strongly associated with schizophrenia and 22q11 DiGeorge syndrome. Missense mutations in the PRODH1 gene found in patients with type I hyperprolinemia were characterized and shown to result in mild to severe reduction in proline dehydrogenase activity. Mutations associated with schizophrenia were found to have a severe reduction in proline dehydrogenase activity indicating that dysfunctional proline dehydrogenase may be a risk factor in schizophrenia. The mechanism by which aberrant proline dehydrogenase and proline metabolism possibly contributes to mental disorders is not known. Novel therapeutics aimed at maintaining normal proline levels in the central nervous system may be a worthwhile strategy for treating certain cases of schizophrenia.

Proline levels in the gastric juice of patients infected with H. pylori were reported to be 10-fold higher than in control subjects. Proline has been shown to be a preferred substrate of H. pylori in the gut. We and others have shown that knocking out the putA gene in Helicobacter significantly reduces infection rates and inflammation of the liver in mice relative to wild-type Helicobacter strains, indicating that PutA and proline metabolism is important for virulence. Thus, inhibiting PutA/proline dehydrogenase with small molecules such as tetrahydro-2-furoic acid, a competitive inhibitor of proline dehydrogenase, may be beneficial for treating infections of H. pylori, the causative agent of peptic ulcers.

**NADPH oxidase**

NADPH oxidase enzymes share a catalytic core comprising a FAD cofactor, two heme cofactors, and a transmembrane domain anchor. In the reaction catalyzed by NADPH oxidase, a hydride is transferred from NADPH to FAD followed by single electron transfer steps from the reduced FAD to the hemes, where molecular oxygen is reduced to superoxide. The overall electron transfer pathway involving NADPH (\(E_m = -320 \text{ mV}\), FAD (\(E_{\text{red}/\text{ox}} = -256 \text{ mV}, E_{\text{sq/red}} = -304 \text{ mV}\)), heme (\(E_m = -245 \text{ mV}\)), and the dioxygen/superoxide couple (\(E_m = -160 \text{ mV}\)) is thermodynamically favored. The transmembrane domain orients NADPH oxidase to enable electron flow across the membrane, with NADPH oxidation occurring on one side of the membrane and reduction of dioxygen occurring on the opposite side. Thus, electrons are effectively shuttled from cytosolic NADPH to molecular oxygen in intracellular or extracellular compartments. The physiological function of NADPH oxidase was originally considered only to be the phagocyte respiratory burst to kill invading microorganisms. With the discovery of several NADPH oxidase isoforms, additional cellular functions beyond host defense have now emerged.

**NADPH oxidase subunits and regulation**

The NADPH oxidase family of enzymes is comprised of seven isoforms (NADPH oxidase 1–5 and Duox1 and 2) which all share a redox catalytic core and a transmembrane binding domain. Previous reviews have provided excellent summaries of the structural features and regulation of the different NADPH oxidase isoforms. Here we will only provide a brief summary.

Nox2 (also known as gp91phox) is the isoform of NADPH oxidase expressed in white blood cells and is responsible for the respiratory burst associated with the phagocytic killing of microbes. Nox2 forms a heterodimer with p22phox, a membrane-associated subunit, to form a complex known as flavocytochrome b558. Regulatory subunits involved in activating Nox2/p22phox are p47phox, p67phox, p40phox, and Rac1/Rac2. Upon cell activation, these regulatory subunits assemble with Nox2/p22phox to form an active NADPH oxidase complex. The formation of an active Nox2 complex is GTP-dependent via Rac1/Rac2 and is upregulated by phosphorylation of cytosolic factors, p47phox and p40phox. Phosphorylated p47phox then binds the p67phox subunit to provide a binding site for GTP-Rac which then results in activation of Nox2 enzyme.

Nox1 forms a heterodimer with p22phox and is activated by regulatory subunits Nox1 (NADPH oxidase organizer 1, analogous to p47phox), Nox1 (NADPH oxidase activator 1, homolog of p67phox), and GTP-Rac1. Nox1 and Nox2 function in host defense by protecting against invasive pathogenic bacteria in the colonocytes. Nox3 activity relies on p22phox and is primarily regulated by Noxa1. Nox4 also requires p22phox but appears to be active without any regulatory subunits. Thus, it has been suggested that Nox4/p22phox is constitutively active. Nox4 has been confirmed to have a role in mitochondrial dysfunction and cardiac damage...
during pressure overload. Recently, a role for Nox4 in DNA damage induced by conditional overexpression of oncogenic H-Ras in primary human thyrocytes was reported.

Nox5 is distinguished by four EF-hand motifs in the N-terminus on the intracellular side of the membrane that allow regulation of NADPH oxidase activity by calcium. Duox 1 and 2 have two EF-hand motifs and an N-terminal extracellular peroxidase homology domain. Similar to Nox5, the EF-hand motifs of Duox 1 and 2 are on the intracellular membrane side, allowing for activation by calcium binding. The function of the peroxidase domain is not fully known because residues important for peroxidase activity are lacking. However, the peroxidase domain has been proposed to have superoxide dismutase activity which would facilitate the conversion of superoxide into hydrogen peroxide, the substrate for thyroperoxidase, which is essential for hormone synthesis.

Apoptosis and signaling

NADPH oxidase isoforms have been shown to have beneficial and detrimental effects, depending on the type and amount of reactive oxygen species generated. NADPH oxidase enzymes can differentially modulate the intracellular redox state and impact cell signaling pathways that promote cell survival or apoptosis. Regulated reactive oxygen species generation is necessary for redox signaling, while prolonged reactive oxygen species generation favors apoptotic pathways. Figure 3 highlights how reactive oxygen species generated by the activation of NADPH oxidase lead to apoptosis. Several studies using different mammalian cell types have shown that NADPH oxidase activity inactivates protein tyrosine phosphatase. Downregulation of protein tyrosine phosphatase results in activation of the receptor tyrosine kinase and downstream pathways, such as extracellular signal-regulated kinase/mitogen activated protein kinase, c-Jun N-terminal kinase, and phosphatidylinositol 3-kinase/Akt (a serine/threonine protein kinase), which regulate cell survival and apoptosis in response to stress. Thus, NADPH oxidase-generated reactive oxygen species, presumably H\(_2\)O\(_2\), can serve as a signaling molecule that mediates cell adaptation to stress and life/death outcomes.

**Figure 3** NADPH oxidase and apoptotic signaling. Protein kinase C/Akt can activate Nox1 and Nox2 by phosphorylation of cytosolic subunits such as p47\(^{phox}\). Activated Nox1 and Nox2 produce superoxide radical (O\(_2^−\)) which dismutates to hydrogen peroxide (H\(_2\)O\(_2\)). NADPH oxidase-generated H\(_2\)O\(_2\) acts as a signaling molecule that affects signaling pathways leading to apoptosis. H\(_2\)O\(_2]/reactive oxygen species generated by NADPH oxidase inactivates protein tyrosine phosphatase, which indirectly activates the ERK, MAPK, and c-Jun N-terminal kinase pathways of apoptosis. NADPH oxidase-generated H\(_2\)O\(_2\) can also activate apoptotic signal-regulating kinases, increase AIF-CypA interactions, and increase protein and DNA damage resulting in apoptosis.

**Abbreviations:** Nox, NADPH oxidase; AIF, apoptosis-inducing factor; PTP, protein tyrosine phosphatase; CypA, cyclophilin A; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; ASK, apoptosis signal-regulating kinase; JNK, c-Jun N-terminal kinase.
NADPH oxidase-generated reactive oxygen species have also been shown to stimulate the secretion of cyclophilin A (a main player in AIF-DNA binding complex) resulting in activation of extracellular signal-regulated kinase/mitogen activated protein kinase. \(^{128}\) NADPH oxidase-generated reactive oxygen species also upregulate AIF gene expression during cerulein-induced apoptosis in rat pancreatic acinar cells. \(^{129}\) Nox1 has been shown to facilitate formation of the TNF-\(\alpha\)-TNF receptor type 1 complex which includes associated death domain protein, receptor interacting protein, and Rac, resulting in c-Jun N-terminal kinase-mediated apoptosis. \(^{112,130}\) Nox4 has also been shown to be involved in TNF-\(\alpha\) mediated apoptosis in cerebral vascular endothelial cells. \(^{131}\) Nox2 in macrophages and Nox4 in astrocytes result in reactive oxygen species which activates apoptosis by activating the apoptosis signal-regulating kinase 1-\(p38\) mitogen activated protein kinases/c-Jun N-terminal kinase pathway leading to apoptosis. \(^{117,132}\) Recently, DR4 and DR5 have been shown to activate Nox1 directly, independent of death-inducing signaling complex-mediated apoptosis. Here, NADPH oxidase-generated superoxide was responsible for the sustained activation of c-Jun N-terminal kinase-dependent apoptosis. \(^{133,134}\)

NADPH oxidase and disease

Involvement of NADPH oxidase in the pathogenesis of several diseases is well established. The most familiar case is Nox2 (gp91phox) deficiency, which causes chronic granulomatous disease, a primary immunodeficiency affecting phagocytosis of the innate immune system. \(^{135,136}\) Patients with chronic granulomatous disease are more susceptible to certain types of bacterial and fungal infections due to dysfunctional phagocytes that lack proper NADPH-dependent superoxide formation. \(^{136}\) Mice deficient in Nox2 develop symptoms of granulomatous disease as well, but also display a second phenotype of balance disorder due to dysfunctional otoconia formation. \(^{135}\) This suggests that Nox2 is involved in oticonium formation, a structure in the utricle of the inner ear, which helps in sensing gravity and linear acceleration. \(^{135}\)

Evidence for NADPH oxidase-derived reactive oxygen species contributing to the progression of cardiovascular disease, \(^{137}\) pulmonary diseases, lung cancer, \(^{138}\) human atherosclerosis, \(^{139}\) myocardial angiogenesis in ischemic heart disease, \(^{140}\) and angiotensin II-initiated apoptosis of neonatal cardiomyocytes \(^{141}\) have been reported. In humans, atherosclerosis is associated with increased Nox1 and Nox2 expression. \(^{142}\) Atherogenic particles such as oxidized low-density lipoprotein have been shown to induce NADPH oxidase-dependent endothelial cell activation and injury which is the underlying cause of atherosclerotic plaque formation. \(^{143,144}\) Similar to oxidized low-density lipoprotein, advanced glycation end products can induce NADPH oxidase activity, leading to increased reactive oxygen species and induction of apoptosis in a caspase 3-dependent manner during diabetic retinopathy. \(^{133,134,145}\) In addition, the advanced glycation end product precursor, 3-deoxyglucosone, induces stress in the endoplasmic reticulum and apoptosis in dermal fibroblasts through activation of Nox4. \(^{146}\)

Therapeutic outlook

Recent comprehensive reviews have discussed the inhibition of NADPH oxidase as a therapeutic target for cardiovascular disease, diabetes, fibrosis, hyperlipidemia, Alzheimer’s disease, and \(\beta\)-cell dysfunction. \(^{136,147-151}\) Here, we will provide some of the recent advances and perspectives.

Reactive oxygen species derived from Nox1 were shown to activate murine hepatic stellate cells. \(^{152,153}\) Activated hepatic stellate cells produce extracellular matrix proteins which lead to liver fibrosis. \(^{154}\) Recently, it was shown that Nox1 knockout mice are less susceptible to liver injury and fibrosis. \(^{155}\) The mechanism of liver injury and fibrosis associated with Nox1 was proposed to involve reactive oxygen species inactivation of phosphatase and tensin homolog (PTEN). Inactivation of PTEN leads to enhanced signaling of pathways involving the Akt/Fork head family of transcription factor Class O (Foxo4) to induce cell proliferation. \(^{155}\) NADPH oxidase enzyme activity has also been reported to lead to activation of pancreatic stellate cells and subsequent pancreatic fibrosis and inflammation in mice. \(^{156}\) Thus, targeting Nox1 may have therapeutic benefits for treatment of chronic liver and pancreatic fibrosis.

In contrast with apoptosis, Nox4 appears to have an important role in cancer cell growth and survival which can influence disease progression. Upregulation of Nox4 activity by overexpression of Akt in melanoma cells leads to increased cancer metastasis. \(^{157}\) Reactive oxygen species generated by Nox4 inhibits apoptosis of pancreatic cancer cells. \(^{158}\) Downregulation of Nox4 by AMPK was shown in a mouse model of type 1 diabetes, suggesting that low Nox4 activity may be a contributing factor in diabetes. \(^{159}\) The prosurvival role of NADPH oxidase has also been documented in prostate cancer cells \(^{160}\) and ovarian cancer cells. \(^{161}\) Thus, inhibition of the specific NADPH oxidase isoform would be a potential therapeutic strategy for the treatment of cancer.
Inhibition of NADPH oxidase in animal models was demonstrated with diphenyl iodonium, an inhibitor that disrupts the physiological oxidative half-reaction by acting as an alternative electron acceptor for reduced FAD. However, diphenyl iodonium is a nonspecific inhibitor of NADPH oxidase because it also inhibits several other flavoproteins, including mitochondrial complexes I and III, cytochrome P450 oxidoreductase, xanthine oxidase, and nitric oxide synthase.147,162,163 Another inhibitor of NADPH oxidase is the natural organic compound, apocynin, which can decrease superoxide production by Nox2 in phagocytes. Apocynin inhibits the assembly of activated Nox2 by interfering with interactions between the Nox2/p22phox heterodimer and the regulatory subunits, p47phox and p67phox.164 However, using apocynin as an NADPH oxidase inhibitor in nonphagocyte cell types is somewhat controversial. Apocynin has been reported to function as an antioxidant in vascular smooth muscle cells by forming an apocynin radical which then scavenges reactive oxygen species.165 In contrast, another group reported that apocynin helps generate reactive oxygen species in nonphagocytic cell types.166

One strategy that was pursued for specific inhibition of Nox1 and 2 was targeting p22phox interactions with the regulatory subunit p47phox which is essential for the activation of Nox1 and Nox2.118,121,167 Targeting the activation of Nox1 and 2 may be therapeutically useful for the diseases in which Nox1 and 2 activation have pathological consequences. Thus, synthetic peptides designed to interfere with p22phox–p47phox interactions have been tested. Synthetic peptides containing the p47phox interacting domain of Nox2 conjugated to the HIV transactivator transcription protein were shown to decrease superoxide production by Nox2 in phagocytes.168 Although peptide inhibitors of NADPH oxidase show promising effects in animal models, oral bioavailability and immune response over long-term use remains an open question.

New potent compounds developed by pharmaceutical companies such as pyrazolopyridines (GKT-136901 and GKT137891)169 and triazolopyrimidines (VAS2870 and VAS3947) have been reported to inhibit NADPH oxidase, with IC₅₀ values below the μM range, and are bioavailable through oral administration.147,163 These compounds are proposed to be competitive inhibitors of NADPH oxidase with respect to NADPH. However, the above compounds appear to lack NADPH oxidase isoform specificity.151 Further studies are required to elucidate the clinical efficacy and safety of these NADPH oxidase inhibitors.

**Conclusion**

The three flavoproteins discussed here are involved in different pathways of apoptosis. Various approaches for manipulating AIF, proline dehydrogenase, and NADPH oxidase activity have been pursued in efforts to enhance or diminish apoptosis in the context of different diseases. Strategies for developing therapeutics involving AIF, proline dehydrogenase, and NADPH oxidase need to consider the multifaceted and complex roles of these enzymes in different cell types. Upregulation of AIF and proline dehydrogenase apoptotic mechanisms may be useful for developing novel adjuvant therapies in cancer treatment. Interestingly, blocking human AIF in combination with small molecule inhibitors of PutA/proline dehydrogenase may also be of therapeutic use in fighting intestinal pathogenic bacterial colonization/infections. The wide ranging physiological roles of NADPH oxidase provide unique opportunities for targeting specific NADPH oxidase isoforms in the treatment of several diseases, in particular cardiovascular disease, diabetes, and Alzheimer’s disease.

**Acknowledgment**

This work was supported in part by a grant from the National Institutes of Health (GM079393).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–257.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267(5203):1456–1462.
3. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397(6718):441–446.
4. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383–424.
5. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2(6):420–430.
6. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet. 1999;33:29–55.
7. Jiang X, Wang X. Cytochrome C-mediated apoptosis. Cell Death Differentiation. 2000;7:239–257.
8. Lorenzo HK, Susin SA. Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Drug Resist Update. 2007;10(6):235–255.
9. Solary E, Droin N, Bettaieb A, Corcos L, Dimanche-Boitrel M, Garrido C. Positive and negative regulation of apoptotic pathways by cytoxic agents in hematological malignancies. Leukemia. 2000;14(10):1833–1849.
10. Zhang X, Vallabhaneni R, Loughran PA, et al. Changes in FADD levels, distribution, and phosphorylation in TNF alpha-induced apoptosis in hepatocytes is caspase-3, caspase-8 and BID dependent. Apoptosis. 2000;13(8):983–992.
11. Thomas LR, Stillman DJ, Thorburn AR. Regulation of Fas-associated death domain interactions by the death effector domain identified by a modified reverse two-hybrid screen. J Biol Chem. 2002;277(37): 34343–34348.

12. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res. 2010;16(6):1701–1708.

13. Fan TJ, Han LH, Cong RS, Liang J. Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai). 2005;37(11):719–727.

14. Ramachandran A, Madesh M, Balasubramanian KA. Apoptosis in the intestinal epithelium: its relevance in normal and pathophysiological conditions. J Gastroenterol Hepatol. 2000;15(2):109–120.

15. Sakata S, Sakamaki K, Watanabe K, et al. Involvement of death receptor Fas in germ cell degeneration in gonads of Kit-deficient Wv/Wv mutant mice. Cell Death Differ. 2003;10(6):676–686.

16. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell. 2010;37(3):299–310.

17. Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol. 2007;8(5):405–413.

18. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008;27(48): 6194–6206.

19. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature. 2001;412(6842):95–99.

20. Li H, Zha H, Xu C, Yuan J. Cleavage of Bid by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94(4):491–501.

21. Ott M, Norberg E, Zhivotovsky B, Orrenius S. Mitochondrial targeting of tBid/Bax: a role for the TOM complex? Cell Death Differ. 2009;16(8):1075–1082.

22. Festjens N, van Gurp M, Van Loo G, Saelens X, Vandenabeele P. Noxa induces apoptosis-inducing factor stability during endoplasmic reticulum stress-induced cell death. EMBO J. 2002;21(12):2977–2988.

23. Chen M, He H, Zhan S, Krajewski S, Reed JC, Gottlieb RA. Bid is a modified reverse two-hybrid screen. Nat Cell Biol. 2002;4(12):1040–1045.

24. Modjtahedi N, Giordanetto F, Madeo F, Kroemer G. Apoptosis-inducing factor stability during endoplasmic reticulum stress-induced cell death. EMBO J. 2002;21(12):2977–2988.

25. Liu L, Xing D, Chen WR. Micro-calpain regulates caspase-independent programed necrosis by interacting with histone H2A.Z. J Biol Chem. 2004;279(24):25579–25586.

26. Vahsen N, Cande C, Dupaigne P, et al. Physical interaction of mitochondrial intermembrane space proteins in apoptotic cell death. Acta Haematol. 2004;111(1–2):7–27.

27. Yin XM, Bid, a BH3-only multi-functional molecule, is at the cross road of life and death. Gene. 2006;369(1):7–19.

28. Llambi F, Green DR. Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev. 2011;21(1):12–20.

29. Chen M, He H, Zhan S, Krajewski S, Reed JC, Gottlieb RA. Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. J Biol Chem. 2001;276(33):30724–30728.

30. Joza N, Pospisilik JA, Hangen E, et al. AIF: not just an apoptosis-inducing factor. FEBS Lett. 2002;512(2):183–189.

31. Klein JA, Longo-Guess CM, Rossmann MP, et al. The hHarlequin mouse mutation downregulates apoptosis-inducing factor. Nature. 2002;419(6905):367–374.
58. Yu SW, Wang Y, Frydenlund DS, Ottersen OP, Dawson VL, Dawson TM. Outer mitochondrial membrane localization of apoptosis-inducing factor: mechanistic implications for release. ASN Neuro. 2009;1(5):e0021.

59. Zanna C, Ghelli A, Porcelli AM, et al. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain. 2008;131(Pt 2):352–367.

60. Matsumori Y, Hong SM, Aoyama K, et al. Hsp70 overexpression protects against indomethacin-induced gastric lesions. J Biol Chem. 2008;284(29):19705–19715.

61. Cui CU, Kim TS, Kwon OJ, et al. Polymorphisms of heat shock protein 70 gene (HSP70) in protecting against indomethacin-induced gastric lesions. J Biol Chem. 2009;284(29):19705–19715.

62. Flynn AN, Wang A, McKay DM, Buret AG. Apoptosis-inducing factor contributes to epithelial cell apoptosis induced by enteropathogenic Escherichia coli. Can J Physiol Pharmacol. 2011;89(2):143–148.

63. Flynn AN, Buret AG. Tight junctional disruption and apoptosis in an in vitro model of Citrobacter rodentium infection. Microb Pathog. 2008;45(2):98–104.

64. Xiao CY, Chen M, Zsengeller Z, Szabo C. Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction. Proc Natl Acad Sci U S A. 2000;97(24):13009–13014.

65. Park YC, Jeong JH, Park KJ, et al. Sulindac activates nuclear factor-kappaB (NF-kB) and induces apoptosis in human gastric cancer cells. J Biol Chem. 2002;277(36):33069–33077.

66. Ashktorab H, Dashwood RH, Dashwood MM, et al. H. pylori infection of epithelial cells. Cell Microbiol. 2003;5(7):1127–1138.

67. Millan A, Huerta S. Apoptosis-inducing factor and colon cancer. J Surg Res. 2009;151(1):163–170.

68. Schmitt E, Maintz G, Puig PE, et al. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res. 2006;66(4):1419–1417.

69. Hamasaki M, Hishida T, Tassone P, et al. Azaspiracine (NN-diethyl-8, 8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005;105(11):4470–4476.

70. Wang M, Zhang L, Han X, et al. Atipimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007;109(12):5455–5462.

71. Park YC, Jeong JH, Park KJ, et al. Sulindac activates nuclear translocation of AIF, DFF40 and endonuclease G but not induces oligonucleosomal DNA fragmentation in HT-29 cells. Life Sci. 2005;77(16):2059–2070.

72. Huang JM, Donald SP, Pandhare J, Liu Y. The metabolism of proline, a stress substrate, modulates carcinoic pathways. Amino Acids. 2008;35(4):681–690.

73. Arentson BW, Sanay N, Becker DF. Substrate channeling in proline metabolism. Front Biosci. 2012;17:375–388.

74. Pham JM, Liu W, Zabirnyk O. Proline metabolism and microenviron-mental stress. Am J Physiol. 2010;30(4):441–463.

75. Small WC, Jones ME. Pyrrolidine 5-carboxylate dehydrogenase of the mitochondrial matrix of rat liver. Purification, physical and kinetic characteristics. J Biol Chem. 1990;265(30):18668–18672.
101. Chiachiccia F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle. 2010;9(6):1091–1096.
102. Krishnan N, Becker DF, Dickman MB. Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress. Free Radical Biol Med. 2008;44(4):671–681.
103. Liu W, Zahirnyk O, Wang H, et al. miR-23b* targets proline oxidase, a novel tumor suppressor protein in renal cancer. Oncogene. 2010;29(35):4914–4924.
104. Willis A, Bender HU, Steel G, Valle D. PRODH variants and risk for schizophrenia. Amino Acids. 2008;35(4):673–679.
105. Jacquet H, Demily C, Houy E, et al. Hyperprolinemia is a risk factor for schizoaffective disorder. Mol Psychiatry. 2005;10(5):479–485.
106. Jacquet H, Raux G, Thibaut F, et al. PRODH mutations and hyperprolinemia in a subset of schizophrenia patients. Hum Mol Genet. 2002;11(19):2243–2249.
107. Karayiorgou M, Simon TJ, Gogos JA. 22q11.2 microdeletions: linking structure, function and inhibition. Biochem J. 2001;357(Pt 3):593–615.
108. Nakajima K, Inatsu S, Mizote T, et al. Possible involvement of putA gene in Helicobacter pylori colonization in the stomach and motility. Biomed Res. 2008;29(1):9–18.
109. Krishnan N, Doster AR, Duhamel GE, Becker DF. Characterization of a Helicobacter hepaticus putA mutant strain in host colonization and oxidative stress. Infect Immun. 2008;76(7):3037–3044.
110. Brown DJ, Griendling KK. Nox proteins in signal transduction. Free Radic Biol Med. 2009;47(9):1229–1253.
111. Nakajima K, Inatsu S, Mizote T, et al. Possible involvement of putA gene in Helicobacter pylori colonization in the stomach and motility. Biomed Res. 2008;29(1):9–18.
112. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: roles in cellular stress response, stress tolerance, and tissue regeneration. Antioxid Redox Signal. 2007;18(2):441–454.
113. Cross AR, Jones OTG, Harper AM, Segal AW. Oxidation-reduction potentials of the flavin and its participation in NADPH oxidase. J Biol Chem. 1986;261(20):9426–9432.
114. Cross AR, Jones OTG, Harper AM, Segal AW. Oxidation-reduction potentials of the cytochrome-B found in the plasma-membrane fraction of human-neutrophils – a possible oxidase in the respiratory burst. Biochem J. 1981;194(2):599–606.
115. Fulton DJ. Nox5 and the regulation of cellular function. Antioxid Redox Signal. 2005;11(10):2443–2452.
116. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov. 2011;10(6):453–471.
117. Jiang F, Zhang Y, Dusting GJ. NADPH oxidase-oxidized mediators: potential role in the inflammatory response. Redox Rep. 2012;17(2):115–127.
118. Takeya R, Ueno N, Kami K, et al. Novel human homologues of Nox5 and the regulation of cellular function. Mol Biol Cell. 2008;19(19):4723–4734.
119. Ueyama T, Tsutsumi T, Kikuchi T, et al. A regulated adaptor function of p47phox and p67phox in the respiratory burst. J Biol Chem. 2001;276(32):25224–25246.
120. Johnson JL, Park JW, Benna JE, Faust LRP, Inanami O, Babior BM. Activation of p47 phox, a cytosolic subunit of the leucocyte NADPH oxidase. J Biol Chem. 1998;273(52):31547–31552.
121. Royal CR, Gutierrez A, Young BM, et al. Detection of p47PHOX activity by site-specific phosphorylation: Akt-dependent activation of the NADPH oxidase. Proc Natl Acad Sci U S A. 2003;100(9):5130–5135.
122. Lopes LR, Dagher MC, Gutierrez A, et al. Phosphorylated p40PHOX as a negative regulator of NADPH oxidase. Biochemistry. 2004;43(12):3723–3730.
123. Kim KA, Kim JY, Lee YA, Song KJ, Min D, Shin MH. NOX1 participates in ROS-dependent cell death of colon epithelial Caco2 cells induced by Entamoeba histolytica. Microbes Infect. 2011;13(12–13):1052–1061.
124. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A. 2010;107(35):15565–15570.
125. Weyemi U, Lagente-Chavalleri O, Fournie-Meunier P, et al. ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene. August 15, 2011. [Epub ahead of print.]
126. Babior BM. NADPH oxidase. Curr Opin Immunol. 2004;16(1):42–47.
127. Ris-Stalpers C. Physiology and pathophysiology of the DUOXes. Antioxid Redox Signal. 2006;8(9–10):1563–1572.
128. Pendyala S, Natarajan V. Redox regulation of Nox proteins. Respir Physiol Neurobiol. 2010;174(3):265–271.
129. Yu JH, Kim KH, Kim H. Role of NADPH oxidase and calcium in cerulium-induced apoptosis: involvement of apoptosis-inducing factor. Ann N Y Acad Sci. 2006;1090:292–297.
130. Matsuzawa A, Saegusa K, Noguchi T, et al. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol. 2005;6(6):578–592.
131. Basuroy S, Bhattacharya S, Leffler CW, Parfenova H, Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular endothelial cells. Am J Physiol Cell Physiol. 2009;296(3):C422–C432.
132. Noguchi T, Ishii K, Fukutomi H, et al. Requirement of reactive oxygen species-dependent activation of ASK1-p38 MAPK pathway for extracellular ATP-induced apoptosis in macrophage. J Biol Chem. 2008;283(12):7657–7665.
133. Park JK, Lee CH, Kim A, Jeong KJ, Kim CH, Kim YS. Death receptors 4 and 5 activate Nox1 NADPH oxidase through riboflavin kinase to induce reactive oxygen species-mediated apoptotic cell death. J Biol Chem. December 9, 2011. [Epub ahead of print.]
134. Mustapha NM, Tarr JM, Kohner EM, Chibber R. NADPH oxidase versus mitochondria-derived ROS in glucose-induced apoptosis of pericytes in early diabetic retinopathy. J Ophthalmol. 2010;2010:746978.
135. Nakano Y, Longo-Guess CM, Bergstrom DE, Nauseef WM, Jones SM, Banfi B. Mutation of the Cyba gene encoding p22phox causes vestibular and immune defects in mice. J Clin Invest. 2008;118(3):1176–1185.
136. de Oliveira-Junior EB, Bustamante J, Newburger PE, Condino-Neto A. The human NADPH oxidase: primary and secondary defects impairing the respiratory burst function and the microbicidal ability of phagocytes. Scand J Immunol. 2011;73(5):420–427.
137. Cave AC, Brewer AC, Narayanananicker A, et al. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal. 2006;8(5–6):691–728.
138. Griffith B, Pendyala S, Hecker L, Lee PJ, Natarajan V, Than Nickel VL. NOX enzymes and pulmonary disease. Antioxid Redox Signal. 2009;11(10):2505–2516.
139. Sorescu D, Weiss D, Lassègue B, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 2002;105(12):1429–1435.
140. Uschio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 2008;266(1):37–52.
141. Grishko V, Pastukh V, Solodushko V, Gillespie M, Azuma J, Schaffer S. Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage. Am J Physiol Heart Circ Physiol. 2003;285(6):H2364–H2372.
142. Sheehan AL, Carrell S, Johnson B, Stanic B, Banfi B, Miller FJ Jr. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis. 2011;216(2):321–326.
143. Heinloth A, Heermeier K, Raff U, Wanner C, Galle J. Stimulation of NADPH oxidase by oxidized low-density lipoprotein induces proliferation of human vascular endothelial cells. J Am Soc Nephrol. 2000;11(10):1819–1825.

144. Carmina R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III2–III7.

145. Gotoh N, Niki E. Rates of interactions of superoxide with vitamin E, vitamin C and related compounds as measured by chemiluminescence. Biochim Biophys Acta. 1992;1115(3):201–207.

146. Loughlin DT, Artlett CM. Precursor of advanced glycation end products mediates ER-stress-induced caspase-3 activation of human dermal fibroblasts through NAD(P)H oxidase 4. PLoS One. 2010;5(6):e11093.

147. Jaquet V, Scapozza L, Clark RA, Krause KH, Lambeth JD. Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal. 2009;11(10):2535–2552.

148. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today. 2006;11(12):524–533.

149. Guichard C, Moreau R, Pessayre D, Epperson TK, Krause KH. NOX family NADPH oxidases in liver and in pancreatic islets: a role in the metabolic syndrome and diabetes. Biochem Soc Trans. 2008;36(Pt 5):920–929.

150. Leito TL, Morand S, Hurt D, Ueyama T. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antioxid Redox Signal. 2009;11(10):2607–2619.

151. Kim JA, Neupane GP, Lee ES, Jeong BS, Park BC, Thapa P. NADPH oxidase inhibitors: a patent review. Expert Opin Ther Pat. 2011;21(8):1147–1158.

152. Guimaraes EL, Empsen C, Geerts A, van Grunsven LA. Advanced glycation end products mediates ER-stress-induced caspase-3 activation of pancreatic stellate cells. Antioxid Redox Signal. 2009;11(10):2535–2552.

153. Ping J, Li JT, Liao ZX, Shang L, Wang H. Indole-3-carbinol inhibits proliferation of stellate cells and aggravates liver fibrosis induced by bile duct ligation. Biochim Biophys Acta. 2007;1722(2):143–147.

154. Friedman SL. Liver fibrosis – from bench to bedside. J Hepatol. 2005;43(2):389–397.

155. Friedman SL. Liver fibrosis – from bench to bedside. J Hepatol. 2010;52(3):389–397.

156. Friedman SL. Liver fibrosis – from bench to bedside. J Hepatol. 2003;38(1):S38–S53.

157. Friedman SL. Liver fibrosis – from bench to bedside. J Hepatol. 2010;52(3):389–397.

158. Guzmán A, Matsuno K, Iwata K, et al. NOX1/nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase promotes proliferation of stellate cells and aggravates liver fibrosis induced by bile duct ligation. Hepatology. 2011;53(3):948–958.

159. Masamune A, Watanabe T, Kikuta K, Satoh K, Shimosegawa T. NADPH oxidase plays a crucial role in the activation of pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G99–G108.